AcelRx Pharmaceuticals (ACRX) announced that it has completed patient enrollment in the two remaining Phase 3 studies of pain med ARX-04, SAP302 and SAP303. SAP302 is a 76-subject, single-arm, open-label study in patients with moderate-to-severe acute pain associated with trauma or injury. The primary endpoint is the time-weighted summed pain intensity difference (SPID) to baseline over the first hour, or SPID1. The company expects to report top-line data from the study in the third quarter.